ArticleFrontiers in genetics2025
The hidden in plain sight: global, regional, and national trends in the pediatric burden of Klinefelter syndrome, 1990-2021.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Klinefelter syndrome (KS) is the most common sex chromosome aneuploidy in males, but its epidemiology in children and adolescents remains poorly characterized worldwide. This study provides the first comprehensive global, regional, and national assessment of KS prevalence and disability-adjusted life years (DALYs) in individuals under 20 years from 1990 to 2021. Methods: We extracted data on KS prevalence and DALYs for individuals under 20 years of age from the Global Burden of Disease (GBD) 2021 database, covering 204 countries and territories. We evaluated temporal trends using the estimated annual percentage change (EAPC), stratified by age group, geographic region, and sociodemographic index (SDI) level. Findings: Between 1990 and 2021, the global number of KS cases in children and adolescents increased from 589,674 (95% UI, 440,342-770,284) to 690,885 (518,462-899,583), a 17.2% rise, while the overall prevalence rate per 100,000 remained stable (26.1 in 1990 to 26.2 in 2021). The global DALY burden attributed to KS rose by 20% over three decades, with marked disparities across SDI levels: in 2021, prevalence rates ranged from 17.1 per 100,000 (low-SDI) to 32.5 per 100,000 (high-SDI), and DALY rates varied from 0.05 to 0.15 per 100,000 across regions. High-SDI countries reported higher prevalence and DALY rates, likely reflecting superior diagnostic capacity and access to genetic services. In contrast, most low- and middle-SDI regions showed minimal changes in prevalence rates, despite increases in absolute case numbers, suggesting persistent underdiagnosis. Notably, children under 1 year of age and adolescents aged 15-19 represented the groups with the highest (49.5 per 100,000) and lowest (17.6 per 100,000) prevalence, respectively. Interpretation: KS continues to represent a largely undetected pediatric health burden, especially in low- and middle-SDI settings. The findings highlight the urgent need for enhanced awareness, early detection strategies, and equitable access to genetic services in global child health policy. Timely diagnosis and intervention can help prevent long-term developmental and health-related consequences of KS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.